Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Clinical Immunology · Autosomal Dominant Agammaglobulinemia Type 5

Standard of Care and Treatment for AGM5

At a Glance

People with AGM5 usually need lifelong antibody replacement, given through a vein (IVIG) or under the skin (SCIG), to reduce infections. Doses are adjusted to infection history and response; live vaccines are avoided, while inactivated vaccines are generally safe.

Managing Agammaglobulinemia 5 (AGM5) is a lifelong commitment to protecting your health by replacing what your immune system cannot produce on its own. Because your body lacks B cells, it cannot create the antibodies (immunoglobulins) needed to fight germs [1]. The goal of treatment is to provide you with immunity that helps keep you healthy and prevents long-term complications [2].

The Cornerstone: Immunoglobulin Replacement Therapy (IgRT)

The most important part of your care is Immunoglobulin Replacement Therapy (IgRT). This treatment uses antibodies collected from thousands of healthy donors to provide you with a broad range of protection against common viruses and bacteria [3].

There are two primary ways to receive this therapy, and the choice depends on your preference, your veins, and how your body reacts to the medicine:

  • Intravenous Immunoglobulin (IVIG): Delivered directly into a vein, usually at a hospital or infusion center. It is typically given once every 3 to 4 weeks [4]. Because it provides a large dose all at once, your antibody levels will “peak” right after the infusion and slowly drop to a “trough” (the lowest level) until the next one [5].
  • Subcutaneous Immunoglobulin (SCIG): Delivered under the skin, often at home using a small pump. These infusions are smaller and happen more frequently—usually once a week or every 1–2 weeks [6]. SCIG provides more consistent antibody levels without the high peaks and low troughs of IVIG [7].

IgRT Safety and Side Effects

Like all medical treatments, IgRT carries risks. Common side effects include headache, flu-like symptoms, and (with SCIG) local swelling or redness at the injection site. Rare but important risks include aseptic meningitis (a non-infectious inflammation around the brain), blood clots (thrombosis), hemolysis (breakdown of red blood cells), and kidney injury. Seek urgent medical care if you experience a severe headache, chest pain, difficulty breathing, or dark urine after an infusion.

Individualizing Your Dose

Your doctor will measure your IgG trough level to help guide your treatment. While general guidelines sometimes reference a trough level of 500–800 mg/dL, there is no universal AGM5-specific target [8][9]. Dosing is product- and patient-specific.

The most important measure of success is your clinical response. If you are still getting frequent infections, or if you have existing lung damage like bronchiectasis, your doctor may increase your dose or frequency regardless of your lab numbers [9][10].

Managing Infections

Even with replacement therapy, breakthrough infections can occur.

  • Prompt Antibiotics: Your team should assess you promptly and start empiric antibiotics when a bacterial infection is suspected. Whenever feasible, your doctor should culture the infection (test a sample of mucus, blood, or skin) to identify the specific germ, without delaying treatment if you are seriously ill [11][12]. Not every fever or cough is bacterial; enteroviral infections, for example, require a different approach.
  • Prophylactic Antibiotics: If you continue to get infections, your doctor may prescribe a daily low-dose antibiotic (such as azithromycin) to prevent germs from taking hold [13][14]. This decision is highly individualized and carries risks, including drug interactions, QT prolongation (changes to heart rhythm), hearing or gastrointestinal side effects, and antimicrobial resistance.

Important Vaccination Rules

Because your immune system functions differently, vaccination practices must be adjusted:

  • Live Vaccines are Contraindicated: You should not receive live attenuated vaccines (such as MMR, oral rotavirus, or the nasal spray flu vaccine). Because you lack B cells, these weakened viruses could potentially grow unchecked and cause illness [15].
  • Inactivated Vaccines: Vaccines like the “flu shot” or COVID-19 vaccines are generally safe and should not be dismissed. While your body cannot make antibodies in response, they may still provide partial T-cell protection [16][17].
  • Household Contacts: People living with you should be fully vaccinated with inactivated vaccines to protect you. Your immunologist should provide specific guidance on whether your contacts can safely receive live vaccines [15].

Common questions in this guide

What is the main treatment for AGM5?
The main treatment is lifelong immunoglobulin replacement therapy, which supplies antibodies collected from healthy donors. It helps protect against infections because people with AGM5 cannot make the antibodies their bodies need.
Should I choose IVIG or SCIG for AGM5?
IVIG is given into a vein, usually every 3 to 4 weeks, while SCIG is given under the skin, often weekly or every 1 to 2 weeks. The best choice depends on your preferences, vein access, schedule, and how you respond to treatment.
How is the immunoglobulin dose decided for AGM5?
Your clinician may check the IgG trough level, which is the lowest antibody level before the next infusion, but there is no single AGM5-specific target. The dose and schedule are adjusted to your infection history and clinical response, including whether you have lung damage such as bronchiectasis.
What happens if I get an infection while receiving immunoglobulin?
Breakthrough infections can still happen, so suspected bacterial infections should be assessed promptly and treated with antibiotics when appropriate. A sample may be cultured to identify the germ when feasible, but treatment should not be delayed if you are seriously ill because some infections, such as enterovirus, need a different approach.
Which vaccines should people with AGM5 avoid?
Live weakened vaccines, including MMR, oral rotavirus, and the nasal-spray flu vaccine, should not be given to people with AGM5 because absent B cells may allow the weakened virus to grow. Inactivated flu shots and COVID-19 vaccines are generally safe, although they may not produce a normal antibody response.
What side effects after an immunoglobulin infusion need urgent care?
Headache, flu-like symptoms, and redness or swelling at a SCIG injection site can occur. Seek urgent medical care for a severe headache, chest pain, trouble breathing, or dark urine, which can signal a rare serious complication.

Get notified when new evidence is published on agammaglobulinemia 5, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Exclusive Characteristics of the p.E555K Dominant-Negative Variant in Autosomal Dominant E47 Deficiency.

    Utsumi T, Tsumura M, Yashiro M, et al.

    Journal of clinical immunology 2024; (44(7)):167 doi:10.1007/s10875-024-01758-x.

    PMID: 39073655
  2. 2

    X-linked agammaglobulinemia: ınvestigation of clinical and laboratory findings, novel gene mutations and prevention of ınfective complications in long-term follow-up.

    Yıldırım İ, Topyıldız E, Bilgin RBG, et al.

    American journal of clinical and experimental immunology 2021; (10(1)):37-43.

    PMID: 33815962
  3. 3

    Immunoglobulin therapy for immunodeficiency.

    Wilson BE, Freeman CM

    Allergy and asthma proceedings 2024; (45(5)):364-370 doi:10.2500/aap.2024.45.240053.

    PMID: 39294913
  4. 4

    A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.

    Han SP, Lin YF, Weng HY, et al.

    Frontiers in immunology 2019; (10()):1953 doi:10.3389/fimmu.2019.01953.

    PMID: 31481959
  5. 5

    Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.

    Pecoraro A, Ricci S, Vultaggio A, et al.

    Clinical drug investigation 2020; (40(3)):279-286 doi:10.1007/s40261-020-00885-8.

    PMID: 32036588
  6. 6

    Clinical and laboratory observation on immunoglobulin replacement therapy switching from an intravenous to a subcutaneous route in a Malaysian X-linked agammaglobulinemia patient.

    Adli A, Wahab AA, Abdul Latiff AH, et al.

    The Medical journal of Malaysia 2022; (77(1)):95-97.

    PMID: 35087003
  7. 7

    Intravenous and subcutaneous immunoglobulin G replacement therapy.

    Bonilla FA

    Allergy and asthma proceedings 2016; (37(6)):426-431 doi:10.2500/aap.2016.37.3987.

    PMID: 27931296
  8. 8

    [X-linked agammaglobulinemia: experience in a Portuguese hospital].

    Fernandes A, Guedes M, Vasconcelos J, et al.

    Anales de pediatria (Barcelona, Spain : 2003) 2015; (82(3)):166-71.

    PMID: 25443324
  9. 9

    Current Spectrum of Infections in Patients with X-Linked Agammaglobulinemia.

    Paccoud O, Mahlaoui N, Moshous D, et al.

    Journal of clinical immunology 2021; (41(6)):1266-1271 doi:10.1007/s10875-021-01043-1.

    PMID: 33880703
  10. 10

    Bronchiectasis, Low IgG Levels and Lack of Vaccination are Risk Factors for Covid-19 Hospitalization in X-linked Agammaglobulinemia - A Retrospective Multicenter Study.

    Stenlander C, Lindahl H, Wahren-Borgström E, et al.

    Journal of clinical immunology 2025; (45(1)):161.

    PMID: 41240154
  11. 11

    Ecthyma gangrenosum due to Pseudomonas aeruginosa sepsis as initial manifestation of X-linked agammaglobulinemia: a case report.

    Huang H, Bai K, Fu Y, et al.

    BMC pediatrics 2020; (20(1)):540 doi:10.1186/s12887-020-02436-8.

    PMID: 33261572
  12. 12

    A rare cause of cellulitis and bacteremia by Achromobacter xylosoxidans in a patient with X-linked agammaglobulinemia: a case report.

    Wagle L, Aryal E, Bruges P, et al.

    Annals of medicine and surgery (2012) 2025; (87(12)):8940-8943 doi:10.1097/MS9.0000000000004093.

    PMID: 41377235
  13. 13

    X-linked Agammaglobulinemia.

    Suri D, Rawat A, Singh S

    Indian journal of pediatrics 2016; (83(4)):331-7 doi:10.1007/s12098-015-2024-8.

    PMID: 26909497
  14. 14

    A Registry Study of 240 Patients with X-Linked Agammaglobulinemia Living in the USA.

    Hernandez-Trujillo V, Zhou C, Scalchunes C, et al.

    Journal of clinical immunology 2023; (43(6)):1468-1477 doi:10.1007/s10875-023-01502-x.

    PMID: 37219739
  15. 15

    Vaccination in PADs.

    Milito C, Soccodato V, Collalti G, et al.

    Vaccines 2021; (9(6)) doi:10.3390/vaccines9060626.

    PMID: 34207916
  16. 16

    Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.

    van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, et al.

    The Journal of allergy and clinical immunology 2022; (149(6)):1949-1957 doi:10.1016/j.jaci.2022.04.002.

    PMID: 35421449
  17. 17

    Response to mRNA COVID-19 vaccination in three XLA patients.

    Squire JD, Joshi AY

    Vaccine 2022; (40(36)):5299-5301 doi:10.1016/j.vaccine.2022.07.046.

    PMID: 35934578

This page is for informational purposes only and does not constitute medical advice. An immunologist should tailor your AGM5 treatment, antibiotics, and vaccination plan to your infection history.